Purchase this article with an account.
K. Fujisato, A. Otani, M. Sasahara, Y. Yodoi, H. Aikawa, H. Tamura, A. Tsujikawa, N. Yoshimura; Long-Term Results of Photodynamic Therapy for Choroidal Neovascularization in Young Patients. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2676.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the safety and efficacy of photodynamic therapy (PDT) with verteporfin in treating choroidal neovascularization (CNV) in young Japanese patients.
We performed a retrospective analysis of 10 eyes of 10 patients (all female) aged 50 years or younger with the diagnosis of CNV. The average age was 35.0±10.7 (ranged 19 to 47 year old) years. Eight eyes were idiopathic and 2 were myopic origin. Five eyes were treated by PDT (Mean 2.6 times). The visual, clinical, angiographic responses and complications were investigated. Mean follow-up periods were 33.2±13.5 (ranged 22 to 57 months) months.
Final best-corrected visual acuity (BCVA) ranged 0.08 to 1.2 and seven eyes (70%) retained final BCVA of 0.5 or more. In changes of BCVA, 40% (2 eyes) were improved, 40% (2 eyes) showed no change, and 20% (1 eye) worsened in both PDT-treated and non-treated groups. The initial mean BCVA was significantly worse in PDT treated group than non-PDT treated group (0.56 vs. 0.21, P=0.029). The mean CNV size was significantly larger in PDT treated group (1716 µm vs. 782 µm, P=0.015). In non-PDT treated group, 3 eyes (60%) had juxtafoveal CNV and 1 eye (20%) had extrafoveal CNV. Only one eye developed subfoveal CNV during follow-up periods. In contrast, all five eyes in PDT-treated group involved subfoveal region. No serious local or systemic complications were encountered.
PDT seems to be a good treatment strategy in achieving a stable or improved vision for young CNV patients, even if they had worse visual acuity or large CNV in their initial visits. Further prospective studies are expected.
This PDF is available to Subscribers Only